In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months --
https://finance.yahoo.com/news/kite-tecartus-car-t-cell-121500630.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.